[Journal of Hepatocellular Carcinoma] In this study, investigators sought to determine how socioeconomic differences influenced outcomes for patients in Florida with HCC. They found that despite having lower socioeconomic status, Hispanic patients with HCC fared better than both black and white patients with HCC.
Analysis of a cohort from the KEYNOTE-240 trial showed that health-related quality of life for patients with HCC was similar across the 2 arms of the study.
[OncoTargets and Therapy] This systematic review and meta-analysis compared MWA and RFA in the treatment of minimally invasive liver cancer. Local tumor progression, technique efficacy, OS, DFS, intrahepatic de novo lesions, extrahepatic metastases, length of stay, and complications were analyzed.
[Journal of Hepatocellular Carcinoma] Although prognosis is poor for patients with hepatocellular carcinoma (HCC), especially those with cirrhosis, a prolonged subclinical growth period offers a window of time for curative treatment. In this review, researchers discuss the current status of screening, and what can be done to improve its potential.
[Journal of Hepatocellular Carcinoma]
The Breakthrough Therapy designation was based on updated interim results from the multicenter, open-label, phase 1b KEYNOTE-524/Study 116 trial .
[Cancer Management and Research] The aim of this study was to establish a prognostic estimation of CHCs after resection (PECAR) score predicting recurrence on the basis of the clinicopathological data.
The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
An analysis of results from the NHS and the HPFS showed that regular use of aspirin — standard-dose 325-mg tablets — reduced hepacellular carcinoma in a dose-dependent manner.
[Journal of Hepatocellular Carcinoma] A review of the manifestations, treatments, and challenges associated with hepatocellular cancer pain.
